PT91397A - Processo de preparacao de polipeptideos sinteticos e de anticorpos relacionados com o antigenio nuclear do virus de epstein-barr - Google Patents

Processo de preparacao de polipeptideos sinteticos e de anticorpos relacionados com o antigenio nuclear do virus de epstein-barr

Info

Publication number
PT91397A
PT91397A PT9139789A PT9139789A PT91397A PT 91397 A PT91397 A PT 91397A PT 9139789 A PT9139789 A PT 9139789A PT 9139789 A PT9139789 A PT 9139789A PT 91397 A PT91397 A PT 91397A
Authority
PT
Portugal
Prior art keywords
epstein
synthetic
barr virus
nuclear antigen
polipeptidees
Prior art date
Application number
PT9139789A
Other languages
English (en)
Other versions
PT91397B (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PT91397A publication Critical patent/PT91397A/pt
Publication of PT91397B publication Critical patent/PT91397B/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16211Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16211Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT91397A 1988-08-09 1989-08-07 Processo de preparacao de polipeptideos sinteticos e de anticorpos relacionados com o antigenio nuclear do virus de epstein-barr PT91397B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/230,250 US5717065A (en) 1984-08-08 1988-08-09 Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen

Publications (2)

Publication Number Publication Date
PT91397A true PT91397A (pt) 1990-03-08
PT91397B PT91397B (pt) 1995-05-04

Family

ID=22864499

Family Applications (1)

Application Number Title Priority Date Filing Date
PT91397A PT91397B (pt) 1988-08-09 1989-08-07 Processo de preparacao de polipeptideos sinteticos e de anticorpos relacionados com o antigenio nuclear do virus de epstein-barr

Country Status (13)

Country Link
US (1) US5717065A (pt)
EP (1) EP0428629B1 (pt)
AT (1) ATE134648T1 (pt)
AU (1) AU643188B2 (pt)
CA (1) CA1340446C (pt)
DE (1) DE68925819T2 (pt)
DK (1) DK175828B1 (pt)
ES (1) ES2018909A6 (pt)
FI (1) FI102381B1 (pt)
GR (1) GR890100501A (pt)
NO (1) NO309720B1 (pt)
PT (1) PT91397B (pt)
WO (1) WO1990001495A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008224A1 (en) * 1989-11-24 1991-06-13 The Council Of The Queensland Institute Of Medical Research Im peptides
JPH04310861A (ja) * 1991-04-09 1992-11-02 Kazuo Yanagi 抗ebna抗体の測定方法および抗ebna抗体測定キット
US5965353A (en) * 1992-09-14 1999-10-12 Akzo Nobel N.V. Epstein-Barr virus peptides and antibodies against these peptides
US5833991A (en) * 1995-04-10 1998-11-10 Cobra Therapeutics, Ltd. Glycine-containing sequences conferring invisibility to the immune system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686282A (en) * 1983-08-12 1987-08-11 Immunetech, Inc. Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors
US5116725A (en) * 1984-08-08 1992-05-26 Scripps Clinic And Research Foundation Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides
US4654419A (en) * 1984-08-08 1987-03-31 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
ZA846192B (en) * 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents

Also Published As

Publication number Publication date
ES2018909A6 (es) 1991-05-16
NO910479L (no) 1991-04-05
PT91397B (pt) 1995-05-04
FI910587A0 (fi) 1991-02-07
CA1340446C (en) 1999-03-16
ATE134648T1 (de) 1996-03-15
NO910479D0 (no) 1991-02-07
AU643188B2 (en) 1993-11-11
DK175828B1 (da) 2005-03-14
US5717065A (en) 1998-02-10
NO309720B1 (no) 2001-03-19
DK21191D0 (da) 1991-02-07
EP0428629A1 (en) 1991-05-29
AU4400089A (en) 1990-03-05
DE68925819T2 (de) 1996-10-02
EP0428629A4 (en) 1991-12-27
FI102381B (fi) 1998-11-30
GR890100501A (el) 1991-12-30
DE68925819D1 (de) 1996-04-04
DK21191A (da) 1991-04-04
WO1990001495A1 (en) 1990-02-22
EP0428629B1 (en) 1996-02-28
FI102381B1 (fi) 1998-11-30

Similar Documents

Publication Publication Date Title
SG47062A1 (en) Synthetic antigens for the detection of antibodies to hepatitis virus
NZ219113A (en) Hiv peptide containing epitope of the env protein
DK532284A (da) Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser
FI20021626A (fi) Immuunimäärityksen reagenssi ja menetelmä hepatiitti C-viruksen (HCV) vasta-aineiden havaitsemiseksi
CA2025598A1 (en) Chimaeric hepadnavirus core antigen proteins
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
ES545971A0 (es) Un metodo para analizar los anticuerpos anti-ebna en una muestra corporal.
CA2004478A1 (en) Monoclonal antibodies to feline-t-lymphotropic lentivirus
HUT44619A (en) Process for preparing monoclonal antibodies and peptides suitable for the treatment and detection of hiv infections
CA2129747A1 (en) Peptide for diagnosing and immunizing against t. cruzi infection
CA2111325A1 (en) Detection of mammalian immunodeficiency viruses
PT91397A (pt) Processo de preparacao de polipeptideos sinteticos e de anticorpos relacionados com o antigenio nuclear do virus de epstein-barr
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus
KR950032286A (ko) B형 간염 바이러스에 대한 인체면역 조절기능을 가진 펩타이드

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19941007

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20091007